Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Futu Holdings Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Futu Holdings Ltd trades at $95.69 (market cap $13.51B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FUTU | |
|---|---|---|
Market Cap | $39.89B | $13.51B |
Sector | Health | Financials |
52-Week High | $491.22 | $199.04 |
52-Week Low | $278.09 | $89.76 |
Enterprise Value | $38.15B | $13.36B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Futu Holdings trades at $96.33, down 0.71% on the day, with a neutral technical signal and key support at $95. The company reported strong 2025 revenue of $22.85 billion and net income of $11.34 billion, with high profitability margins. However, recent earnings misses and a securities class action lawsuit have introduced uncertainty.
The outlook is mixed: solid fundamentals and a 'Buy' analyst consensus support upside, but legal risks and earnings volatility pose significant headwinds. Investors should weigh the attractive valuation against potential regulatory and litigation overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
